List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1395443/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Production and auto-induction of transforming growth factor-α in human keratinocytes. Nature, 1987, 328, 817-820.	13.7	843
2	TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell, 1990, 61, 777-785.	13.5	601
3	Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology. 2011. 29. 2598-2607.	0.8	550
4	Calciphylaxis: Natural history, risk factor analysis, and outcome. Journal of the American Academy of Dermatology, 2007, 56, 569-579.	0.6	454
5	Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomas. Journal of the American Academy of Dermatology, 2002, 46, 95-106.	0.6	448
6	Integrated control of growth and differentiation of normal human prokeratinocytes cultured in serum-free medium: Clonal analyses, growth kinetics, and cell cycle studies. Journal of Cellular Physiology, 1984, 121, 31-44.	2.0	399
7	Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis. Mayo Clinic Proceedings, 2007, 82, 364-380.	1.4	331
8	Trichothiodystrophy: Update on the sulfur-deficient brittle hair syndromes. Journal of the American Academy of Dermatology, 2001, 44, 891-924.	0.6	281
9	Photoprotection. Lancet, The, 2007, 370, 528-537.	6.3	281
10	Adrenergic and Cholinergic Control in the Biology of Epidermis: Physiological and Clinical Significance. Journal of Investigative Dermatology, 2006, 126, 1948-1965.	0.3	249
11	Cell Density and Culture Factors Regulate Keratinocyte Commitment to Differentiation and Expression of Suprabasal K1/K10 Keratins. Journal of Investigative Dermatology, 1995, 104, 271-276.	0.3	241
12	A Homozygous Nonsense Mutation in the β3 Chain Gene of Laminin 5 (LAMB3) in Herlitz Junctional Epidermolysis Bullosa. Genomics, 1994, 24, 357-360.	1.3	218
13	UVB Activates ERK1/2 and p38 Signaling Pathways via Reactive Oxygen Species in Cultured Keratinocytes. Journal of Investigative Dermatology, 1999, 112, 751-756.	0.3	218
14	New Techniques for the In Vitro Culture of Human Skin Keratinocytes and Perspectives on Their Use for Grafting of Patients With Extensive Burns. Mayo Clinic Proceedings, 1986, 61, 771-777.	1.4	204
15	Monoclonal gammopathies and associated skin disorders. Journal of the American Academy of Dermatology, 1999, 40, 507-535.	0.6	202
16	Melanocytes are not absent in lesional skin of long duration vitiligo. Journal of Pathology, 2000, 191, 407-416.	2.1	198
17	WHIM syndrome, an autosomal dominant disorder: Clinical, hematological, and molecular studies. American Journal of Medical Genetics Part A, 2000, 91, 368-376.	2.4	193
18	Antiphospholipid syndrome and the skin. Journal of the American Academy of Dermatology, 1997, 36, 970-982.	0.6	189

#	Article	IF	CITATIONS
19	Cutaneous manifestations of cryoglobulinemia: Clinical and histopathologic study of seventy-two patients. Journal of the American Academy of Dermatology, 1991, 25, 21-27.	0.6	172
20	H2O2 Is an Important Mediator of UVB-Induced EGF-Receptor Phosphorylation in Cultured Keratinocytes. Journal of Investigative Dermatology, 1998, 110, 966-971.	0.3	172
21	Hydroxyurea dermopathy: A unique lichenoid eruption complicating long-term therapy with hydroxyurea. Journal of the American Academy of Dermatology, 1997, 36, 178-182.	0.6	170
22	Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris–like lesions. Journal of Clinical Investigation, 2000, 106, 1467-1479.	3.9	169
23	Growth of normal human keratinocytes and fibroblasts in serum-free medium is stimulated by acidic and basic fibroblast growth factor. Journal of Cellular Physiology, 1989, 138, 511-518.	2.0	162
24	The clinicopathologic spectrum of lymphomatoid papulosis: Study of 31 cases. Journal of the American Academy of Dermatology, 1983, 8, 81-94.	0.6	161
25	Genome-Wide Expression Profiling of Five Mouse Models Identifies Similarities and Differences with Human Psoriasis. PLoS ONE, 2011, 6, e18266.	1.1	160
26	GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood, 2014, 123, 3007-3015.	0.6	158
27	Livedoid Vasculopathy. Archives of Dermatology, 2006, 142, 1413-8.	1.7	157
28	Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). Journal of the American Academy of Dermatology, 2011, 64, 352-404.	0.6	154
29	Mutations in the rod domain of keratin 2e in patients with ichthyosis bullosa of Siemens. Nature Genetics, 1994, 7, 485-490.	9.4	153
30	Topical tacrolimus in the treatment of symptomatic oral lichen planus: A series of 13 patients. Journal of the American Academy of Dermatology, 2002, 46, 27-34.	0.6	152
31	EGF-Receptor Tyrosine Kinase Inhibition Induces Keratinocyte Growth Arrest and Terminal Differentiation. Journal of Investigative Dermatology, 1997, 109, 751-756.	0.3	149
32	Survival, Risk Factors, and Effect of Treatment in 101 Patients With Calciphylaxis. Mayo Clinic Proceedings, 2016, 91, 1384-1394.	1.4	145
33	Trichothiodystrophy: Review of sulfur-deficient brittle hair syndromes and association with the ectodermal dysplasias. Journal of the American Academy of Dermatology, 1990, 22, 705-717.	0.6	139
34	Detection of circulating T cells with CD4+CD7â^' immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. Journal of the American Academy of Dermatology, 1996, 35, 404-410.	0.6	132
35	Folliculotropic Mycosis Fungoides. Archives of Dermatology, 2010, 146, 607-13.	1.7	132
36	Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. Journal of the American Academy of Dermatology, 2005, 53, 1067-1071.	0.6	131

#	Article	IF	CITATIONS
37	Serum-free culture of normal human melanocytes: Growth kinetics and growth factor requirements. Journal of Cellular Physiology, 1989, 140, 565-576.	2.0	130
38	Autocrine Regulation of Keratinocytes: The Emerging Role of Heparin-Binding, Epidermal Growth Factors. Journal of Investigative Dermatology, 1998, 111, 715-721.	0.3	126
39	Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis. Experimental Dermatology, 2009, 18, 764-770.	1.4	124
40	Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape. Mayo Clinic Proceedings, 2008, 83, 825-846.	1.4	120
41	Catecholamines in Human Keratinocyte Differentiation. Journal of Investigative Dermatology, 1995, 104, 953-957.	0.3	118
42	Clinical and pathologic correlations in 96 patients with panniculitis, including 15 patients with deficient levels of α1-antitrypsin. Journal of the American Academy of Dermatology, 1989, 21, 1192-1196.	0.6	116
43	Production of catecholamines in the human epidermis. Biochemical and Biophysical Research Communications, 1992, 189, 72-78.	1.0	114
44	Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy. Annals of Internal Medicine, 2006, 145, 234.	2.0	113
45	Methotrexate Therapy of Psoriasis: Differential Sensitivity of Proliferating Lymphoid and Epithelial Cells to the Cytotoxic and Growth-Inhibitory Effects of Methotrexate. Journal of Investigative Dermatology, 1995, 104, 183-188.	0.3	112
46	Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: The Mayo Clinic experience, 1998 to 2010. Journal of the American Academy of Dermatology, 2012, 67, e179-e185.	0.6	112
47	Lymphomatoid papulosis: A clinical and histopathologic review of 53 cases with leukocyte immunophenotyping, DNA flow cytometry, and T-cell receptor gene rearrangement studies. Journal of the American Academy of Dermatology, 1994, 30, 210-218.	0.6	111
48	Primary follicular mucinosis: Long-term follow-up of patients younger than 40 years with and without clonal T-cell receptor gene rearrangement. Journal of the American Academy of Dermatology, 2002, 47, 856-862.	0.6	108
49	The Pathophysiological Significance of Nondesmoglein Targets of Pemphigus Autoimmunity. Archives of Dermatology, 1998, 134, 971-80.	1.7	106
50	Perilesional linear atrophy and hypopigmentation after intralesional corticosteroid therapy. Journal of the American Academy of Dermatology, 1988, 19, 537-541.	0.6	104
51	T-cell receptor gene rearrangement analysis: Cutaneous T cell lymphoma, peripheral T cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders. Journal of the American Academy of Dermatology, 1991, 25, 787-796.	0.6	103
52	Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. Journal of the American Academy of Dermatology, 2014, 71, 92-99.	0.6	101
53	Paraneoplastic autoimmune multiorgan syndrome: 20 years after. International Journal of Dermatology, 2011, 50, 905-914.	O.5	98
54	Pemphigus Vulgaris Autoantibody Profiling by Proteomic Technique. PLoS ONE, 2013, 8, e57587.	1.1	92

#	Article	IF	CITATIONS
55	GROWTH FACTORS IN HAIR ORGAN DEVELOPMENT AND THE HAIR GROWTH CYCLE. Dermatologic Clinics, 1996, 14, 559-572.	1.0	91
56	Pemphigus Vulgaris IgG and Methylprednisolone Exhibit Reciprocal Effects on Keratinocytes. Journal of Biological Chemistry, 2004, 279, 2135-2146.	1.6	91
57	Alpha-1-antitrypsin deficiency and panniculitis. American Journal of Medicine, 1988, 84, 80-86.	0.6	90
58	Tissue Plasminogen Activator for Treatment of Livedoid Vasculitis. Mayo Clinic Proceedings, 1992, 67, 923-933.	1.4	90
59	Suprabasal expression of human amphiregulin in the epidermis of transgenic mice induces a severe, early-onset, psoriasis-like skin pathology: Expression of amphiregulin in the basal epidermis is also associated with synovitis. Experimental Dermatology, 2004, 13, 347-356.	1.4	90
60	Growth factor-independent proliferation of normal human neonatal keratinocytes: Production of autocrine- and paracrine-acting mitogenic factors. Journal of Cellular Physiology, 1991, 146, 277-289.	2.0	88
61	Expression Profiling of UVB Response in Melanocytes Identifies a Set of p53-Target Genes. Journal of Investigative Dermatology, 2006, 126, 2490-2506.	0.3	86
62	Incidence of skin cancers in patients with atopic dermatitis treated with coal tar. Journal of the American Academy of Dermatology, 1980, 3, 612-615.	0.6	85
63	H2O2 is required for UVB-induced EGF receptor and downstream signaling pathway activation. Free Radical Biology and Medicine, 1999, 27, 1197-1202.	1.3	81
64	A population-based study of the association between bullous pemphigoid and neurologic disorders. Journal of the American Academy of Dermatology, 2014, 71, 1191-1197.	0.6	81
65	Cocaine abuse: Dermatologic manifestations and therapeutic approaches. Journal of the American Academy of Dermatology, 2008, 59, 483-487.	0.6	80
66	Pemphigus Vulgaris Acantholysis Ameliorated by Cholinergic Agonists. Archives of Dermatology, 2004, 140, 327-34.	1.7	78
67	Free Radical Reduction by Thioredoxin Reductase at the Surface of Normal and Vitiliginous Human Keratinocytes. Journal of Investigative Dermatology, 1986, 87, 728-732.	0.3	75
68	UVB-induced Epidermal Growth Factor Receptor Phosphorylation is Critical for Downstream Signaling and Keratinocyte Survival¶. Photochemistry and Photobiology, 2000, 72, 135.	1.3	75
69	Two Functionally Distinct Classes of Growth Arrest States in Human Prokeratinocytes That Regulate Clonogenic Potential. Journal of Investigative Dermatology, 1986, 86, 410-417.	0.3	74
70	Personalized treatment of Sézary syndrome by targeting a novel <i><scp>CTLA</scp>4</i> : <i><scp>CD</scp>28</i> fusion. Molecular Genetics & Genomic Medicine, 2015, 3, 130-136.	0.6	73
71	Pediatric melanoma: Analysis of an international registry. Cancer, 2013, 119, 4012-4019.	2.0	71
72	Localization and Regulation of Pregnancy-Associated Plasma Protein A Expression in Healing Human Skin. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4465-4471.	1.8	70

#	Article	IF	CITATIONS
73	Defective calcium transport in vitiliginous melanocytes. Archives of Dermatological Research, 1996, 288, 11-13.	1.1	69
74	IEX-1, an immediate early gene, increases the rate of apoptosis in keratinocytes. Oncogene, 2001, 20, 7992-7997.	2.6	69
75	Randomized controlled trial of acitretin versus placebo in patients at highâ€risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer, 2012, 118, 2128-2137.	2.0	69
76	Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma. JCO Precision Oncology, 2020, 4, 319-334.	1.5	67
77	Sweat Gland Carcinoma Ex Eccrine Spiradenoma. American Journal of Dermatopathology, 1987, 9, 90-98.	0.3	66
78	High Recurrence Rates of Basal Cell Carcinoma After Mohs Surgery in Patients With Chronic Lymphocytic Leukemia. Archives of Dermatology, 2004, 140, 985-8.	1.7	66
79	Eosinophilic spongiosis: A clinicopathologic review of seventy-one cases. Journal of the American Academy of Dermatology, 1983, 8, 337-343.	0.6	65
80	Follicular mucinosis presenting as an acneiform eruption: Report of four cases. Journal of the American Academy of Dermatology, 1998, 38, 849-851.	0.6	65
81	Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: Experience with 218 patients over 30 years at Mayo Clinic. Journal of the American Academy of Dermatology, 2012, 67, 100-106.	0.6	64
82	Sweet syndrome: Acute febrile neutrophilic dermatosis. Seminars in Dermatology, 1995, 14, 173-178.	0.6	64
83	Monopathogenic vs multipathogenic explanations of pemphigus pathophysiology. Experimental Dermatology, 2016, 25, 839-846.	1.4	63
84	Differential expression of mRNA coding for heparin-binding growth factor type 2 in human cells. Journal of Cellular Physiology, 1988, 136, 297-304.	2.0	61
85	Eosinophilic vasculitis in connective tissue disease. Journal of the American Academy of Dermatology, 1996, 35, 173-182.	0.6	61
86	Constrictive bronchiolitis associated with paraneoplastic autoimmune multiâ€organ syndrome. Respirology, 2009, 14, 129-133.	1.3	61
87	Human EGF Receptor (HER) Family and Heregulin Members Are Differentially Expressed in Epidermal Keratinocytes and Modulate Differentiation. Experimental Cell Research, 2001, 271, 315-328.	1.2	59
88	Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. Journal of the American Academy of Dermatology, 2011, 64, 91-96.	0.6	59
89	Cyclosporine in the Treatment of Dermatologic Disease: An Update. Mayo Clinic Proceedings, 1996, 71, 1182-1191.	1.4	58
90	Overexpression and mutations ofp53 in metastatic malignant melanomas. , 1996, 67, 313-317.		58

#	Article	IF	CITATIONS
91	Up-regulation of Glucosylceramide Synthase Expression and Activity during Human Keratinocyte Differentiation. Journal of Biological Chemistry, 1998, 273, 9651-9655.	1.6	58
92	Low-Dose Tissue Plasminogen Activator for Calciphylaxis. Archives of Dermatology, 2004, 140, 1045.	1.7	58
93	Early cutaneous gene transcription changes in adult atopic dermatitis and potential clinical implications. Experimental Dermatology, 2007, 16, 28-36.	1.4	58
94	A mutational hot spot in keratin 10 (KRT 10) in patients with epidermolytic hyperkeratosis. Human Molecular Genetics, 1993, 2, 2147-2150.	1.4	55
95	Paraneoplastic Pemphigus: A Case of Prolonged Survival. Mayo Clinic Proceedings, 1994, 69, 851-855.	1.4	55
96	Transglutaminase Autoantibodies in Dermatitis Herpetiformis and Celiac Sprue. Journal of Investigative Dermatology, 2008, 128, 332-335.	0.3	55
97	A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. Journal of Clinical Investigation, 2004, 114, 1090-1097.	3.9	55
98	H2O2 mediates oxidative stress-induced epidermal growth factor receptor phosphorylation. Toxicology Letters, 2001, 122, 205-214.	0.4	54
99	Physiological effects of ultrasound mist on fibroblasts. International Journal of Dermatology, 2007, 46, 587-593.	0.5	54
100	Cutaneous small-vessel vasculitis associated with solid organ malignancies: The Mayo Clinic experience, 1996 to 2009. Journal of the American Academy of Dermatology, 2012, 66, e55-e65.	0.6	54
101	Lymphoma versus pseudolymphoma of the skin: Gene rearrangement study of 21 cases with clinicopathologic correlation. Journal of the American Academy of Dermatology, 1993, 29, 945-953.	0.6	53
102	Malignant Basomelanocytic Tumor Manifesting as Metastatic Melanoma. American Journal of Surgical Pathology, 2004, 28, 1393-1396.	2.1	53
103	Quantitative assessment of scleroderma by surface wave technique. Medical Engineering and Physics, 2011, 33, 31-37.	0.8	53
104	Sézary syndrome: A study of 176 patients at Mayo Clinic. Journal of the American Academy of Dermatology, 2012, 67, 1189-1199.	0.6	53
105	Normal and transformed human prokeratinocytes express divergent effects of a tumor promoter on cell cycle-mediated control of proliferation and differentiation. Carcinogenesis, 1985, 6, 1181-1187.	1.3	52
106	Peptide Vaccination of Patients With Metastatic Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 352-360.	0.6	52
107	Transcriptional Profiling after Lipid Raft Disruption in Keratinocytes Identifies Critical Mediators of Atopic Dermatitis Pathways. Journal of Investigative Dermatology, 2011, 131, 46-58.	0.3	52
108	Amphiregulin Causes Functional Downregulation of Adherens Junctions in Psoriasis. Journal of Investigative Dermatology, 2005, 124, 1134-1140.	0.3	51

#	Article	IF	CITATIONS
109	Acral Melanoma and Mechanical Stress on the Plantar Surface of the Foot. New England Journal of Medicine, 2017, 377, 395-396.	13.9	50
110	Divergent Regulation of the Growth-promoting GeneIEX-1 by the p53 Tumor Suppressor and Sp1. Journal of Biological Chemistry, 2002, 277, 14612-14621.	1.6	49
111	Unusual cutaneous manifestations of B-cell chronic lymphocytic leukemia. Journal of the American Academy of Dermatology, 2009, 60, 772-780.	0.6	48
112	A Novel Immediate Early Response Gene, IEX-1, Is Induced by Ultraviolet Radiation in Human Keratinocytes. Biochemical and Biophysical Research Communications, 1998, 253, 336-341.	1.0	47
113	Association of porphyria cutanea tarda with hereditary hemochromatosis. Journal of the American Academy of Dermatology, 2004, 51, 205-211.	0.6	46
114	High Recurrence Rates of Squamous Cell Carcinoma after Mohs' Surgery in Patients with Chronic Lymphocytic Leukemia. Dermatologic Surgery, 2005, 31, 38-42.	0.4	45
115	High-Cell-Density Phorbol Ester and Retinoic Acid Upregulate Involucrin and Downregulate Suprabasal Keratin 10 in Autocrine Cultures of Human Epidermal Keratinocytes. Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications 1999, 2, 138-144	1.7	44
116	Effectiveness of Intravenous Immunoglobulin Therapy for Skin Disease Other Than Toxic Epidermal Necrolysis: A Retrospective Review of Mayo Clinic Experience. Mayo Clinic Proceedings, 2005, 80, 41-47.	1.4	44
117	Expression of an immediate early gene, IEX-1, in human tissues. Histochemistry and Cell Biology, 2001, 115, 489-497.	0.8	43
118	The Hazards of Moist Toilet Paper. Archives of Dermatology, 2010, 146, 886-90.	1.7	43
119	Delusional Infestation is Typically Comorbid with Other Psychiatric Diagnoses: Review of 54 Patients Receiving Psychiatric Evaluation at Mayo Clinic. Psychosomatics, 2012, 53, 258-265.	2.5	43
120	TORCh syndrome. Seminars in Dermatology, 1995, 14, 179-186.	0.6	43
121	Regulation of a Novel Immediate Early Response Gene,IEX-1,in Keratinocytes by 1α,25-Dihydroxyvitamin D3. Biochemical and Biophysical Research Communications, 1998, 251, 868-873.	1.0	42
122	From Furuncle to Axillary Web Syndrome: Shedding Light on Histopathology and Pathogenesis. Dermatology, 2012, 224, 110-114.	0.9	42
123	Calciphylaxis: A Disease of Pannicular Thrombosis. Mayo Clinic Proceedings, 2016, 91, 1395-1402.	1.4	42
124	Homocysteinemia and livedoid vasculitis. Journal of the American Academy of Dermatology, 1999, 40, 279-281.	0.6	40
125	Isotretinoin Exposure and Risk of Inflammatory Bowel Disease. JAMA Dermatology, 2014, 150, 1322.	2.0	40
126	Keratinocytes Produce and Are Regulated by Transforming Growth Factors. Annals of the New York Academy of Sciences, 1988, 548, 211-224.	1.8	39

#	Article	IF	CITATIONS
127	Human Herpesviruses 6, 7, and 8 From a Dermatologic Perspective. Mayo Clinic Proceedings, 2012, 87, 1004-1014.	1.4	39
128	Secondary neuroendocrine carcinomas of the skin. Journal of the American Academy of Dermatology, 1985, 13, 134-142.	0.6	38
129	Expression of p53 protein in benign and malignant epidermal pathologic conditions. Journal of the American Academy of Dermatology, 1993, 29, 741-748.	0.6	38
130	Microsatellite Instability in Keratoacanthoma. Cancer, 1995, 76, 1765-1771.	2.0	37
131	Recurrent Erythema Multiforme/Stevens-Johnson Syndrome. Archives of Dermatology, 2002, 138, 1547.	1.7	37
132	Vitamin C Derivative Ascorbyl Palmitate Promotes Ultraviolet-B-Induced Lipid Peroxidation and Cytotoxicity in Keratinocytes. Journal of Investigative Dermatology, 2002, 119, 1103-1108.	0.3	37
133	Myelodysplastic Syndrome Presenting as Generalized Granulomatous Dermatitis. Archives of Dermatology, 2011, 147, 331.	1.7	37
134	Sneddon syndrome. Seminars in Dermatology, 1995, 14, 166-172.	0.6	37
135	Loss of Inositol Polyphosphate 5-Phosphatase Is an Early Event in Development of Cutaneous Squamous Cell Carcinoma. Cancer Prevention Research, 2010, 3, 1277-1283.	0.7	36
136	Delusional Infestation, Including Delusions of Parasitosis. Archives of Dermatology, 2011, 147, 1041.	1.7	36
137	1α,25-Dihydroxyvitamin D3Inhibits Normal Human Keratinocyte Growth by Increasing Transforming Growth Factor β2 Release. Biochemical and Biophysical Research Communications, 1996, 229, 618-623.	1.0	34
138	Early clinical manifestations of Sézary syndrome: A multicenter retrospective cohort study. Journal of the American Academy of Dermatology, 2017, 77, 719-727.	0.6	34
139	Human Calmodulin-like Protein Is an Epithelial-Specific Protein Regulated during Keratinocyte Differentiation. Experimental Cell Research, 2001, 267, 216-224.	1.2	33
140	Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: Development of extracutaneous lymphoma in 6 patientsâ^—. Journal of the American Academy of Dermatology, 2005, 52, 991-996.	0.6	33
141	The induction of the alpha-1-adrenoceptor signal transduction system on human melanocytes. Experimental Dermatology, 1996, 5, 20-23.	1.4	32
142	Characterization of Skn-1a/i POU Domain Factors and Linkage to Papillomavirus Gene Expression. Journal of Biological Chemistry, 1997, 272, 15905-15913.	1.6	32
143	Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. Science Translational Medicine, 2020, 12, .	5.8	32
144	Altered catecholamine synthesis and degradation in the epidermis of patients with atopic eczema. Archives of Dermatological Research, 1997, 289, 663-666.	1.1	31

#	Article	IF	CITATIONS
145	Activation of the epidermal growth factor receptor promotes lymphangiogenesis in the skin. Journal of Dermatological Science, 2013, 71, 184-194.	1.0	31
146	Epigenetics in the pathogenesis and pathophysiology of psoriasis vulgaris. Journal of Drugs in Dermatology, 2014, 13, 111-8.	0.4	31
147	Expression and Regulation of mRNA Coding for Acidic and Basic Fibroblast Growth Factor and Transforming Growth Factorα in Cells Derived from Human Skin. Molecular Endocrinology, 1990, 4, 1377-1385.	3.7	30
148	Guideline and quality indicators for development, purchase and use of controlled health vocabularies. International Journal of Medical Informatics, 2002, 68, 175-186.	1.6	30
149	Vitamin E analog modulates UVB-induced signaling pathway activation and enhances cell survival. Free Radical Biology and Medicine, 2001, 30, 425-432.	1.3	28
150	Psoriasis: more than skin deep. Nature Medicine, 2005, 11, 17-18.	15.2	28
151	Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience. International Journal of Dermatology, 2016, 55, e431-9.	0.5	28
152	Deep learning for dermatologists: Part II. Current applications. Journal of the American Academy of Dermatology, 2022, 87, 1352-1360.	0.6	27
153	Efficacy of Vitamin D3 Derivatives in the Treatment of Psoriasis Vulgaris: A Preliminary Report. Mayo Clinic Proceedings, 1993, 68, 835-841.	1.4	26
154	Activated protein C resistance caused by factor V gene mutation: Common coagulation defect in chronic venous leg ulcers?. Journal of the American Academy of Dermatology, 1997, 36, 616-620.	0.6	26
155	Increased Immunoglobulin (Ig) G4–Positive Plasma Cell Density and IgG4/IgG Ratio Are Not Specific for IgG4-Related Disease in the Skin. American Journal of Clinical Pathology, 2014, 141, 234-238.	0.4	26
156	Characterization of a novel hexameric repeat DNA sequence in the promoter of the immediate early gene, IEX-1, that mediates 11±,25-dihydroxyvitamin D3-associated IEX-1 gene repression. Oncogene, 2002, 21, 3706-3714.	2.6	25
157	A Phase II Study of Topical Ceramides for Cutaneous Breast Cancer. Breast Cancer Research and Treatment, 2003, 80, 99-104.	1.1	25
158	A Dose-Escalation Study of Aerosolized Sargramostim in the Treatment of Metastatic Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 573-579.	0.6	25
159	Anti-Psoriatic Drug Anthralin Activates JNK via Lipid Peroxidation: Mononuclear Cells are More Sensitive than Keratinocytes. Journal of Investigative Dermatology, 2000, 114, 688-692.	0.3	24
160	Simultaneous analysis of oxidized and reduced glutathione in cell extracts by capillary zone electrophoresis. Biomedical Chromatography, 2002, 16, 224-228.	0.8	24
161	Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon. JAMA Network Open, 2021, 4, e217934.	2.8	24
162	Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination. Leukemia and Lymphoma, 2021, 62, 2554-2555.	0.6	24

#	Article	IF	CITATIONS
163	Cyclosporine in the treatment of cutaneous T cell lymphoma. Journal of the American Academy of Dermatology, 1990, 23, 1084-1089.	0.6	23
164	Follicular Dendritic Cell Sarcoma With Indolent T-Lymphoblastic Proliferation Is Associated With Paraneoplastic Autoimmune Multiorgan Syndrome. American Journal of Surgical Pathology, 2018, 42, 1647-1652.	2.1	23
165	Adenosine and Adenine Nucleotides Inhibit the Autonomous and Epidermal Growth Factor-Mediated Proliferation of Cultured Human Keratinocytes. Journal of Investigative Dermatology, 1995, 104, 976-981.	0.3	22
166	Human Epidermal Keratinocytes Upregulate Expression of the Prolactin Receptor after the Onset of Terminal Differentiation, but Do Not Respond to Prolactin. Archives of Biochemistry and Biophysics, 1999, 364, 247-253.	1.4	22
167	Progressive generalized alopecia due to systemic amyloidosis. Journal of the American Academy of Dermatology, 2002, 46, 434-436.	0.6	22
168	Cutaneous complications of intravesical treatments for bladder cancer: Granulomatous inflammation of the penis following BCG therapy and penile gangrene following mitomycin therapy. Journal of the American Academy of Dermatology, 2006, 55, 328-331.	0.6	21
169	Eosinophilic vasculitis syndrome: Recurrent cutaneous eosinophilic necrotizing vasculitis. Seminars in Dermatology, 1995, 14, 106-110.	0.6	21
170	Trichothiodystrophy with chronic neutropenia and mild mental retardation. Journal of the American Academy of Dermatology, 1991, 24, 356-358.	0.6	20
171	Gene rearrangement analysis in lymphoid neoplasia. Clinics in Dermatology, 1991, 9, 119-128.	0.8	20
172	Large Sample of Nephrogenic Systemic Fibrosis Cases From a Single Institution. Archives of Dermatology, 2009, 145, 1095-102.	1.7	20
173	A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma. Melanoma Research, 2015, 25, 406-411.	0.6	20
174	Deep learning for dermatologists: Part I. Fundamental concepts. Journal of the American Academy of Dermatology, 2022, 87, 1343-1351.	0.6	20
175	Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study. Journal of Investigative Dermatology, 2022, 142, 2109-2116.e4.	0.3	20
176	Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis. British Journal of Dermatology, 2022, 187, 650-658.	1.4	19
177	Human Papillomavirus Isolated from Transplant-Associated Porokeratoses of Mibelli Responsive to Topical 5% Imiquimod Cream. Dermatologic Surgery, 2006, 32, 858-861.	0.4	18
178	Diagnostic imaging in paraneoplastic autoimmune multiorgan syndrome: retrospective single site study and literature review of 225 patients. International Journal of Dermatology, 2015, 54, 424-437.	0.5	18
179	Prevalence of Delusional Infestation—A Population-Based Study. JAMA Dermatology, 2018, 154, 615.	2.0	18
180	Recombinant Tissue Plasminogen Activator for the Treatment of Cutaneous Infarctions in Antiphospholipid Antibody Syndrome. Angiology, 2001, 52, 635-639.	0.8	17

#	Article	IF	CITATIONS
181	Antipsoriatic drug anthralin induces EGF receptor phosphorylation in keratinocytes: requirement for H2O2 generation. Experimental Dermatology, 2004, 13, 78-85.	1.4	17
182	Fatal Cytotoxic Cutaneous Lymphoma Presenting as Ulcerative Psoriasis. Archives of Dermatology, 2009, 145, 801-8.	1.7	17
183	Clinical and histopathologic features of paraneoplastic granuloma annulare in association with solid organ malignancies: A case–control study. Journal of the American Academy of Dermatology, 2018, 79, 913-920.e1.	0.6	17
184	Calmodulin-Like Protein Upregulates Myosin-10 in Human Keratinocytes and Is Regulated during Epidermal Wound Healing In Vivo. Journal of Investigative Dermatology, 2009, 129, 765-769.	0.3	16
185	The prognostic value of inositol polyphosphate 5-phosphatase in cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 2019, 80, 626-632.e1.	0.6	16
186	Staphylococcal scalded skin syndrome and toxic shock syndrome after tooth extraction. Journal of the American Academy of Dermatology, 2008, 59, 342-346.	0.6	15
187	Sézary syndrome without erythroderma: A review of 16 cases at Mayo Clinic. Journal of the American Academy of Dermatology, 2017, 76, 683-688.	0.6	15
188	Immunolocalization of the Tumor-Sensitive Calmodulin-Like Protein CALML3 in Normal Human Skin and Hyperproliferative Skin Disorders. PLoS ONE, 2013, 8, e62347.	1.1	14
189	Prognostic value of inositol polyphosphate-5-phosphatase expression in recurrent and metastatic cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 2020, 82, 846-853.	0.6	14
190	Improving Access to Care Through the Establishment of a Local, Teledermatology Network. Telemedicine Journal and E-Health, 2020, 26, 935-940.	1.6	14
191	Human papillomavirus in cutaneous squamous cell carcinoma and cervix of a patient with psoriasis and extensive ultraviolet radiation exposure. Journal of the American Academy of Dermatology, 2001, 44, 681-686.	0.6	13
192	Effect of insulin-dependent diabetes mellitus on response to extracorporeal photopheresis in patients with Sézary syndrome. Journal of the American Academy of Dermatology, 2002, 47, 63-67.	0.6	13
193	Structural and functional alterations in the ?2-adrenoceptor are caused by a point mutation in patients with atopic eczema. Experimental Dermatology, 2007, 16, 807-813.	1.4	13
194	Suppression of tissue factor expression, cofactor activity, and metastatic potential of murine melanoma cells by theN-terminal domain of adenovirus E1A 12S protein. Journal of Cellular Biochemistry, 2002, 85, 54-71.	1.2	12
195	Mitosis increases levels of secretory leukocyte protease inhibitor in keratinocytes. Biochemical and Biophysical Research Communications, 2004, 316, 407-410.	1.0	12
196	Clinical Experience with Rituximab and Intravenous Immunoglobulin for Pretibial Myxedema: A Case Series. Thyroid, 2019, 29, 692-699.	2.4	12
197	Growth of Normal Human Melanocytes in a Defined Medium. Pigment Cell & Melanoma Research, 1988, 1, 27-31.	4.0	11
198	Perturbed Epidermal Pterin Metabolism in Hermansky–Pudlak Syndrome. Journal of Investigative Dermatology, 1998, 111, 511-516.	0.3	11

#	Article	IF	CITATIONS
199	Development of myelodysplastic syndrome evolving to acute myeloid leukemia in a patient receiving etanercept for psoriasis. Journal of the American Academy of Dermatology, 2011, 65, 673-674.	0.6	11
200	Cutaneous lymphatics and chronic lymphedema of the head and neck. Clinical Anatomy, 2012, 25, 72-85.	1.5	11
201	Immunomodulation of malignant melanoma by contact sensitizing agents. Expert Review of Clinical Immunology, 2014, 10, 63-76.	1.3	11
202	Extracorporeal Photopheresis and Adjuvant Aerosolized Granulocyte-Macrophage Colony-Stimulating Factor for Sézary Syndrome. Mayo Clinic Proceedings, 2002, 77, 197-200.	1.4	10
203	Defective calcium transport in vitiliginous melanocytes. Archives of Dermatological Research, 1995, 288, 11-13.	1.1	10
204	A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sézary syndrome. American Journal of Clinical Pathology, 2006, 125, 364-74.	0.4	10
205	Generalized Gravis Junctional Epidermolysis Bullosa: Case Report, Laboratory Evaluation, and Review of Recent Advances. Mayo Clinic Proceedings, 1996, 71, 863-868.	1.4	9
206	Impact of standardized templates and skin cancer learning modules for teledermatology consultations. International Journal of Dermatology, 2019, 58, 1423-1429.	0.5	9
207	Clinical and morphological features of necrobiosis lipoidica. Journal of the American Academy of Dermatology, 2022, 86, 1133-1135.	0.6	9
208	Large plantar wart caused by human papillomavirus-66 and resolution by topical cidofovir therapy. Journal of the American Academy of Dermatology, 2000, 43, 340-343.	0.6	9
209	Okadaic acid-induced ECF receptor and MAP kinase activation does not require reactive oxygen species in primary keratinocytes. Archives of Dermatological Research, 2002, 294, 243-245.	1.1	8
210	CD4+CD25+FOXP3+ malignant T cells in Sézary syndrome are not necessarily functional regulatory T cells. Journal of the American Academy of Dermatology, 2013, 69, 485-489.	0.6	8
211	Signalling protein complexes isolated from primary human skinâ€resident <scp>T</scp> cells can be analysed by <scp>M</scp> ultiplex <scp>IP</scp> â€ <scp>FCM</scp> . Experimental Dermatology, 2014, 23, 272-273.	1.4	8
212	Plasmapheresis for refractory urticarial vasculitis in a patient with B-cell chronic lymphocytic leukemia. Journal of Drugs in Dermatology, 2006, 5, 534-7.	0.4	8
213	Coal tar, ultraviolet light, and cancer. Journal of the American Academy of Dermatology, 1981, 4, 234-235.	0.6	7
214	Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with Sézary syndrome. JAAD Case Reports, 2021, 9, 24-27.	0.4	7
215	Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: Diagnosis and management. Journal of the American Academy of Dermatology, 2022, 86, 1167-1169.	0.6	7
216	Culture confluence regulates gene expression of normal human keratinocytes. Wound Repair and Regeneration, 2004, 12, 613-617.	1.5	6

#	Article	IF	CITATIONS
217	Treatment of epidermolysis bullosa pruriginosa using systemic and topical agents. Journal of the American Academy of Dermatology, 2014, 70, e136-e137.	0.6	6
218	Gene Expression Profiling in Cutaneous Melanoma: Caveats for Clinicians. Mayo Clinic Proceedings, 2016, 91, 1147-1148.	1.4	6
219	Thyroid Ophthalmopathy, Dermopathy, and Acropachy. New England Journal of Medicine, 2016, 375, 261-261.	13.9	6
220	Use of Skin Cancer Procedures, Medicare Reimbursement, and Overall Expenditures, 2012-2017. JAMA Network Open, 2020, 3, e2025139.	2.8	6
221	The policy dimensions, regulatory landscape, and market characteristics of teledermatology in the United States. JAAD International, 2020, 1, 202-207.	1.1	6
222	Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine. International Journal of Dermatology, 2002, 41, 352-6.	0.5	6
223	Angiosarcoma in a patient with congenital nonhereditary lymphedema. Cutis, 2012, 90, 248-51.	0.4	6
224	Histopathologic features of necrobiosis lipoidica. Journal of Cutaneous Pathology, 2022, 49, 692-700.	0.7	6
225	Facial edema and crusted patches: A precursor to life-threatening acute systemic lupus erythematosus. Journal of the American Academy of Dermatology, 2007, 56, S126-S127.	0.6	5
226	Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-cell responses in a murine melanoma model. Cytokine, 2010, 49, 287-293.	1.4	5
227	IgG4-Related Skin Disease. JAMA Dermatology, 2013, 149, 1439.	2.0	5
228	Dermatologic Disorders in 118 Patients with Autoimmune (Immunoglobulin G4-Related) Pancreatitis: A Retrospective Cohort Analysis. American Journal of Clinical Dermatology, 2015, 16, 125-130.	3.3	5
229	Pseudo Pemphigus Phenotypes in Mice with Inactivated Desmoglein 3. American Journal of Pathology, 2015, 185, 3125-3127.	1.9	5
230	Density and distribution of acral melanocytic nevi and acral melanomas on the plantar surface of the foot. Journal of the American Academy of Dermatology, 2019, 80, 790-792.e2.	0.6	5
231	Déjà Vu All Over Again: Skin Cap Still Contains a High-Potency Glucocorticosteroid. Archives of Dermatology, 2005, 141, 801-3.	1.7	4
232	Sézary Syndrome. Surgical Pathology Clinics, 2014, 7, 191-202.	0.7	4
233	An effective game-based learning intervention for improving melanoma recognition. Journal of the American Academy of Dermatology, 2018, 79, 587-588.	0.6	4
234	Syringotropic and folliculotropic mycosis fungoides with mycosis fungoides–associated vasculopathic ulcers. JAAD Case Reports, 2019, 5, 231-233.	0.4	4

#	Article	IF	CITATIONS
235	A case of pediatric lymphomatoid papulosis treated with photodynamic therapy and narrowband ultraviolet B. Pediatric Dermatology, 2020, 37, 881-883.	0.5	4
236	Blue light photodynamic therapy with 5-aminolevulinic acid in refractory mycosis fungoides: A prospective, open-label study. Journal of the American Academy of Dermatology, 2021, 85, 969-971.	0.6	4
237	Skin Cancer Knowledge, Attitudes and Sun Protection Practices in the Hispanic Population: A Cross-Sectional Survey. Journal of Racial and Ethnic Health Disparities, 2023, 10, 1293-1303.	1.8	4
238	Novel redistribution of myosin-containing filaments in cultured keratinocytes identified by a human monoclonal autoantibody. In Vitro Cellular & Developmental Biology, 1989, 25, 397-401.	1.0	3
239	The Polymerase Chain Reaction. The Journal of Dermatologic Surgery and Oncology, 1993, 19, 831-845.	0.8	3
240	UVB-induced Epidermal Growth Factor Receptor Phosphorylation is Critical for Downstream Signaling and Keratinocyte Survival ¶. Photochemistry and Photobiology, 2007, 72, 135-140.	1.3	3
241	Case report: Positron emission tomography/computed tomography: use for initial staging of malignant melanoma. International Journal of Dermatology, 2010, 49, 1056-1058.	0.5	3
242	Systemic scleroderma and lupus panniculitis with atypical clinical features: A case report and comprehensive review. JAAD Case Reports, 2018, 4, 789-793.	0.4	3
243	Immunosuppression-associated primary cutaneous plasmablastic lymphoma secondary to romidepsin. JAAD Case Reports, 2020, 6, 19-22.	0.4	3
244	Necrobiosis lipoidica-associated cutaneous malignancy. Journal of the American Academy of Dermatology, 2022, 86, 1428-1429.	0.6	3
245	Primary cutaneous epidermotropic marginal zone B-cell lymphoma treated with total skin electron beam therapy. JAAD Case Reports, 2021, 15, 15-18.	0.4	3
246	How to Sequence Therapies in Mycosis Fungoides. Current Treatment Options in Oncology, 2021, 22, 101.	1.3	3
247	Hyperpigmentationa case study. Australian Family Physician, 2011, 40, 701-2.	0.5	3
248	Regulation of Cellular Growth by 1,25-Dihydroxyvitamin D3-Mediated Growth Factor Expression. Physiology, 1999, 14, 37-40.	1.6	2
249	Acute Carpal Tunnel Syndrome Preceded by 5 Years of Unusual Skin Changes. Archives of Neurology, 2007, 64, 447.	4.9	2
250	Comorbidities and diabetic complications in patients with necrobiosis lipoidica. Journal of the American Academy of Dermatology, 2022, 86, 891-894.	0.6	2
251	WHIM syndrome, an autosomal dominant disorder: Clinical, hematological, and molecular studies. American Journal of Medical Genetics Part A, 2000, 91, 368.	2.4	2
252	Monocytes Promote Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma and Are Recruited to the Tumor Microenvironment by CCL5 (RANTES). Blood, 2008, 112, 378-378.	0.6	2

#	Article	IF	CITATIONS
253	Isotretinoin Exposure and Risk of Celiac Disease. PLoS ONE, 2015, 10, e0135881.	1.1	2
254	Dermoscopic Description of Fibroepithelioma of Pinkus with Negative Network. Dermatology Practical and Conceptual, 2019, 9, 246-247.	0.5	2
255	Iron, genes, and viruses: the porphyria cutanea tarda triple threat. Cutis, 2011, 88, 73-6.	0.4	2
256	Protein Kinase C-Mediated Expression of Transforming Growth Factor-? in Normal Human Keratinocytes. Annals of the New York Academy of Sciences, 1988, 548, 352-353.	1.8	1
257	Plasma Protein Abnormalities and Vascular Lesions. Journal of Dermatology, 1997, 24, 732-733.	0.6	1
258	Thomas B Fitzpatrick MD: 1948–51: The Residency Years and Preparation for Doctoral Thesis: Mayo Clinic. Journal of Investigative Dermatology, 2004, 122, xxii-xxiv.	0.3	1
259	John Martin Wood (1938–2008) – Pioneering biochemist, educator and communicator. Experimental Dermatology, 2008, 17, 579-583.	1.4	1
260	Identification of the Effect of Amphiregulin on Keratinocytes and T Cells in Psoriasis. Psoriasis Forum, 2010, 16a, 4-8.	0.1	1
261	Reply to the Editor—Atrial Fibrillation: An Inflammatory and Autoimmune Disorder. Heart Rhythm, 2012, 9, e2-e3.	0.3	1
262	Comments on: Stricker and Middelveen. Psychosomatics, 2012, 53, 505-506.	2.5	1
263	Concomitant pemphigus herpetiformis and sarcoidosis. JAAD Case Reports, 2016, 2, 436-438.	0.4	1
264	Bexarotene. Mayo Clinic Proceedings, 2021, 96, 2519-2522.	1.4	1
265	Panniculitis in a patient with metastatic renal cell carcinoma on a tyrosine kinase inhibitor. Anti-Cancer Drugs, 2021, 32, 474-475.	0.7	1
266	Epidermal growth factors and cytokines (Clinical Dermatology Series, No. 10). Journal of the American Academy of Dermatology, 1995, 32, 303-304.	0.6	0
267	Cutaneous T-Cell Lymphoma. Mayo Clinic Proceedings, 2003, 78, 1054-1055.	1.4	Ο
268	The Effect of Insulinâ€dependent Diabetes Mellitus on the Efficacy of Extracorporeal Photopheresis in Lateâ€stage Sézary Syndrome. Annals of the New York Academy of Sciences, 2001, 941, 206-209.	1.8	0
269	Risk of Multiple Primary Melanomas. JAMA - Journal of the American Medical Association, 2006, 295, 1516.	3.8	0
270	Epidermal reference genes at the forefront of data interpretation. Experimental Dermatology, 2015, 24, 738-739.	1.4	0

#	Article	IF	CITATIONS
271	Skin-Limited Graft-versus-Host Disease after Pancreatic Transplantation. Case Reports in Transplantation, 2017, 2017, 1-3.	0.1	0
272	Cutaneous Eruption Heralding Squamous Cell Carcinoma of the Lung: Answer. American Journal of Dermatopathology, 2019, 41, 773-774.	0.3	0
273	15591 CD4+ small/medium T-cell lymphoproliferative disorder: A Mayo Enterprise experience. Journal of the American Academy of Dermatology, 2020, 83, AB42.	0.6	0
274	Trends in Medicare utilization and reimbursement for electronic brachytherapy following 2016 billing code changes. Journal of the American Academy of Dermatology, 2021, 84, 1154-1155.	0.6	0
275	26941 The prognostic value of inositol polyphosphate 5-phosphatase in cutaneous squamous cell carcinoma in a random sampling representative of the general population. Journal of the American Academy of Dermatology, 2021, 85, AB26.	0.6	0
276	25713 Ruxolitinib cream in the treatment of cutaneous lichen planus. Journal of the American Academy of Dermatology, 2021, 85, AB10.	0.6	0
277	25240 Cosentyx (secukinumab) for the treatment of adult onset pityriasis rubra pilaris: A single arm, open-label exploratory study. Journal of the American Academy of Dermatology, 2021, 85, AB55.	0.6	0
278	GATA-3 Expression Promotes IL-10 Production, Alternative Macrophage Polarization, and Identifies a Subset Of High-Risk PTCL, NOS. Blood, 2013, 122, 841-841.	0.6	0
279	Consolidation of US dermatology practices. International Journal of Dermatology, 2021, , .	0.5	0
280	Dermoscopic features of cutaneous Langerhans cell histiocytosis. European Journal of Dermatology, 2018, 28, 88-89.	0.3	0